Ascendis Pharma AS (ASND)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$256.82

+3.37 (+1.33%)

Market Cap: $16.97B

Last updated: Nov 06, 2026 at 4:42 PM ET

Earnings

Performance (10Y)

Beat Rate

36%(14/39)

Avg Surprise

-19.72%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$1.12

Range$0.65 - $1.65

4 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$1.32-15.1%

60d ago$0.95+17.6%

30d ago$0.94+19.3%

7d ago$0.94+19.3%

Current$1.12

Revenue Consensus

$367M

Range$352M - $405M

19 analysts

Period ending Dec 31, 2026

EPS Consensus$8.34

Range$1.87 - $13.88

5 analysts

Revenue Consensus

$407M

Range$361M - $543M

20 analysts

Last 12 of 39 reported quarters and 2 upcoming estimates

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$8.34	$1.87 - $13.88	-	-	5	-	-
Sep 30, 2026Sep 26EST	-	$1.12	$0.65 - $1.65	-	-	4	0 1 30d	-
Jun 30, 2026Jun 26 Reported Aug 13, 2026Reported Aug 13	$3.29	$0.78	$0.58 - $0.96	+321.79%	Beat	3	No revisions (30d)	+453.8%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$0.27	$0.43	$0.05 - $0.81	-37.21%	Miss	2	No revisions (30d)	+117.1%
Dec 31, 2025Dec 25 Reported Feb 11, 2026Reported Feb 11	$-0.55	$-0.24	$-2.60 - $0.27	-129.17%	Miss	12	1 7 30d	+14.1%
Sep 30, 2025Sep 25 Reported Nov 12, 2025Reported Nov 12	$-1.00	$-0.12	$-0.83 - $0.27	-733.33%	Miss	11	6 2 30d	+41.9%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-0.93	$-1.42	$-1.91 - $-0.79	+34.51%	Beat	12	6 1 30d	+55.9%
Mar 31, 2025Mar 25 Reported May 1, 2025Reported May 1	$-1.58	$-1.51	$-1.95 - $-1.10	-4.64%	Miss	10	2 1 30d	+31.3%
Dec 31, 2024Dec 24 Reported Feb 12, 2025Reported Feb 12	$-0.64	$-1.17	$-1.78 - $0.23	+45.30%	Beat	12	2 1 30d	+58.4%
Sep 30, 2024Sep 24 Reported Nov 14, 2024Reported Nov 14	$-1.72	$-1.46	$-2.14 - $0.55	-17.81%	Miss	11	1 6 30d	+40.3%
Jun 30, 2024Jun 24 Reported Sep 3, 2024Reported Sep 3	$-2.11	$-1.46	$-2.16 - $-1.04	-44.52%	Miss	12	1 0 30d	+2.3%
Mar 31, 2024Mar 24 Reported May 2, 2024Reported May 2	$-2.30	$-1.42	$-1.42 - $-1.42	-61.97%	Miss	0	No revisions (30d)	-16.2%
Dec 31, 2023Dec 23 Reported Feb 7, 2024Reported Feb 7	$-1.54	$-1.76	$-1.76 - $-1.76	+12.50%	Beat	0	No revisions (30d)	+58.4%
Sep 30, 2023Sep 23 Reported Nov 7, 2023Reported Nov 7	$-2.88	$-2.25	$-2.88 - $-1.85	-28.00%	Miss	11	9 0 30d	+5.0%

Key Metrics

Valuation
P/E Ratio	114.14	EV/EBITDA	192.15x
Price/FCF	45.36x	FCF Yield	2.20%
Profitability
Profit Margin	70.90%	Operating Margin	65.00%
ROE	118.80%	ROIC	3.18%
Financial Health
Debt/Equity	0.31x	Interest Coverage	0.36x
Current Ratio	2.99x	Quick Ratio	2.32x
Trading Statistics
Beta	0.48	Avg Volume	654.47K
52-Week High	$282.15	52-Week Low	$188.07

Technical Indicators Dashboard

Moving Averages

SMA 10$251.22

SMA 20$241.54

SMA 50$242.50

SMA 200$239.03

EMA 10$250.53

EMA 20$245.37

EMA 50$242.98

EMA 200$235.44

MACD

Line: 5.26Signal: 3.27Hist: 1.99

ADX

ADX: 31.5+DI: 25.8-DI: 11.5

Aroon & PSAR

Aroon Up100.0

Aroon Down16.0

PSAR$249.32

Bollinger Bands

Upper Band$264.67

Lower Band$218.41

%B Position1915%(Upper)

Band Width0.83

RSI (14-Day)

Neutral

65.0

Momentum Oscillators

Stoch %K93.0

Stoch %D89.9

Williams %R-5.7

ROC (10d)5.5%

Momentum13.45

CCI (20d)97.4

MFI (14d)74.2

Volatility Measures

ATR (14d)$6.44(2.5%)

StdDev (20d)11.56

Hist Vol21.8%(Moderate)

Volume Flow

VWAP$255.43

OBV-1.2M

AD Line6.7M

CMF (20d)0.165

Volume Metrics

Avg Vol (20d)632.9K

Vol Ratio1.4x

VWMA (20d)$240.70

Pivot Points

R3$262.90

R2$260.42

R1$256.93

Pivot Point$254.45

S1$250.96

S2$248.48

S3$244.99

Advanced Oscillators

TSI22.66

Ultimate Osc57.6

KST63.22

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$344.90M	$250.66M	$245.18M	$213.63M	$158.04M	$100.95M	$173.92M	$57.83M	$36.00M	$95.89M	$137.70M	$48.03M
Cost of Revenue	$32.30M	$21.62M	$27.20M	$22.35M	$31.45M	$17.52M	$14.02M	$11.20M	$11.46M	$7.57M	$19.46M	$7.39M
Gross Profit	$312.61M	$229.03M	$217.98M	$191.28M	$126.60M	$83.44M	$159.89M	$46.63M	$24.53M	$88.33M	$118.25M	$40.65M

Operating Expenses	$249.17M	$203.81M	$208.18M	$180.28M	$179.55M	$187.65M	$159.51M	$143.38M	$157.79M	$137.47M	$154.86M	$175.05M
R&D	$74.65M	$57.63M	$74.98M	$66.88M	$71.99M	$86.60M	$79.30M	$73.54M	$83.48M	$70.69M	$90.88M	$111.44M
SG&A	$171.68M	$145.23M	$135.00M	$111.69M	$105.71M	$95.65M	$78.78M	$68.13M	$72.30M	$72.30M	$63.98M	$62.51M
Operating Income	$63.43M	$25.22M	$9.80M	$11.00M	$-52,951,000	$-104,212,000	$383,000	$-96,743,000	$-133,257,000	$-49,145,000	$-36,611,000	$-134,407,000

Interest Income	$4.83M	$4.52M	$4.37M	$3.33M	$55.06M	$28.85M	$14.90M	$28.28M	$49.05M	$3.58M	$60.13M	$4.14M
Interest Expense	$14.41M	$68.36M	$61.40M	$19.72M	$33.02M	$44.79M	$56.63M	$25.35M	$19.62M	$77.16M	$68.55M	$24.52M
Income Before Tax	$233.90M	$-48,969,254	$-26,454,575	$-57,372,000	$-35,007,000	$-93,565,000	$-37,384,000	$-98,178,000	$-109,151,000	$-128,527,000	$-81,088,000	$-161,578,000
Income Tax Expense	$23.51M	$-688,657,525	$6.79M	$3.62M	$3.85M	$1.06M	$1.08M	$1.02M	$229,000	$2.51M	$5.79M	$645,000

Net Income	$210.40M	$639.69M	$-33,247,273	$-60,989,000	$-38,855,000	$-94,626,000	$-38,469,000	$-99,198,000	$-109,380,000	$-131,035,000	$-86,878,000	$-162,223,000

EBITDA	$68.08M	$23.68M	$39.72M	$-53,353,000	$2.32M	$-44,234,000	$-37,893,000	$-68,457,000	$-85,139,000	$-46,889,000	$-67,686,000	$-132,316,000
EBIT	$63.43M	$19.39M	$34.94M	$-57,372,000	$-1,989,000	$-48,779,000	$-42,368,000	$-72,831,000	$-89,527,000	$-51,366,000	$-72,663,000	$-137,059,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about ASND

News

An EU panel backs rare-disease status for a weekly treatment from Ascendis Pharma (ASND).

The European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending orphan medicinal product designation for Ascendis Pharma's once-weekly TransCon CNP (navepegritide)...

Stock Titan•Nov 6, 2026 4:29 PM ET11/6/26•Bullish

Ascendis Pharma drug gains orphan designation in EU, nearing approval

Ascendis Pharma's TransCon CNP (navepegritide) has received a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) for orphan drug designation in the EU for treating achondroplasia in children....

StreetInsider•Nov 6, 2026 8:29 AM ET11/6/26•Bullish

Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union

Ascendis Pharma A/S announced that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has recommended maintaining orphan medicinal product designation for TransCon CNP (navepegritide)...

The Manila Times•Nov 6, 2026 8:29 AM ET11/6/26•Bullish

A results call is planned for 8 a.m. Eastern on Nov. 12; Ascendis Pharma also plans a business update.

Ascendis Pharma (Nasdaq: ASND) announced its plan to report third-quarter 2026 financial results and provide a business update on November 12, 2026. The results will be released before U.S. financial markets open...

Stock Titan•Nov 5, 2026 4:01 PM ET11/5/26•Neutral

(ASND) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis of Ascendis Pharma A/s (NASDAQ: ASND), identifying strong sentiment across all horizons supporting an overweight bias. It outlines three distinct institutional trading...

Stock Traders Daily•Oct 30, 2026 8:06 PM ET10/30/26•Bullish

ASND Valuation and Fair Value

P/E: 114.1x
Forward P/E: 21.2x
EV/EBITDA: 192.2x
P/FCF: 45.4x
P/B: 10.7x

See GNG's fair value

ASND Profitability: Margins, ROIC and FCF

Gross margin: 90.2%
Operating margin: 65.0%
Net margin: 70.9%
ROIC: 3.2%
ROE: 118.8%
FCF margin: 27.6%
FCF yield: 2.2%

ASND Competitors

Company	Ticker
Hologic Inc	HOLX
Revvity Inc.	RVTY
Medpace Holdings Inc	MEDP
Exelixis Inc	EXEL
EXACT Sciences Corporation	EXAS
Neurocrine Biosciences Inc	NBIX
Zimmer Biomet Holdings Inc	ZBH
ICON PLC	ICLR

Sector: Healthcare

ASND Analyst Ratings

Consensus: Buy
Analysts: 21
Strong Buy: 5
Buy: 15
Hold: 1
Sell: 0
Strong Sell: 0

ASND Bull Case vs Bear Case

Bull case

ASND converts 27.6% of revenue into free cash flow.
ASND has a 70.9% net profit margin.
ASND grew quarterly revenue 114.7% year over year.

Bear case

ASND trades at 114.1x trailing earnings.
ASND beat EPS estimates in 37.5% of its last 8 reported quarters.

ASND Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -65.1%
EPS estimate (fiscal period ending Sep 30, 2026): $1.12
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 0 up, 1 down

ASND Earnings Date

ASND reports Nov 9, 2026, after the close. The date is estimated.

ASND Earnings Call

The latest ASND earnings call transcript on file is labeled 2026Q2.

Read the 2026Q2 transcript

ASND ETF Holders

GNG tracks 7 ETFs that hold ASND. The largest weights:

iShares Biotechnology ETF (IBB), 1.06% of the fund
Invesco NASDAQ Next Gen 100 ETF (QQQJ), 0.71% of the fund
VictoryShares International Free Cash Flow Growth ETF (GRIN), 0.52% of the fund
iShares U.S. Healthcare ETF (IYH), 0.20% of the fund
iShares Russell 1000 Growth ETF (IWF), 0.04% of the fund

Open the ETF Stock Exposure tool for ASND

Frequently Asked Questions About ASND

When does ASND report earnings?

Ascendis Pharma AS (ASND) is expected to report earnings on Nov 9, 2026.

Does ASND pay dividends?

Ascendis Pharma AS (ASND) does not currently pay a regular dividend.

What is ASND's P/E ratio?

Ascendis Pharma AS has a price-to-earnings (P/E) ratio of 114.14.

What is ASND's market cap?

Ascendis Pharma AS (ASND) has a market capitalization of $16.97B with a current stock price of $256.82.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In